Fig. 4From: A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritisImpact of varying model inputs on incremental cost-effectiveness ratio for an add-on B-cell test or magnetic resonance imaging (MRI) in intermediate-risk patients. QALY quality-adjusted life year, ICER incremental cost-effectiveness ratio, FP false positiveBack to article page